| Title |
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
|
|---|---|
| Published in |
Advances in Therapy, August 2012
|
| DOI | 10.1007/s12325-012-0045-5 |
| Pubmed ID | |
| Authors |
Matteo Monami, Valentina Vitale, Maria Luisa Ambrosio, Nadia Bartoli, Giulia Toffanello, Benedetta Ragghianti, Francesca Monami, Niccolò Marchionni, Edoardo Mannucci |
| Abstract |
Lipid profile is an important determinant of cardiovascular risk in type 2 diabetes. It is well known that patients with type 2 diabetes are more likely to be dyslipidemic than the general population. Given the observed connection between glucose and lipid metabolism in patients with type 2 diabetes, it is conceivable that different glucose-lowering agents can have a varying impact on the lipid profile. When metformin monotherapy fails, other drugs can be added to achieve sufficient glycemic control. Available oral agents include pioglitazone, acarbose, dipeptidyl peptidase 4 (DPP-4) inhibitors, and insulin secretagogs. The present meta-analysis was designed to assess the effect of DPP-4 inhibitors, pioglitazone, insulin secretagogs, and acarbose on blood lipids when compared to placebo. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 91 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 19% |
| Researcher | 13 | 14% |
| Other | 8 | 9% |
| Student > Bachelor | 8 | 9% |
| Professor | 7 | 8% |
| Other | 18 | 19% |
| Unknown | 21 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 10% |
| Agricultural and Biological Sciences | 7 | 8% |
| Nursing and Health Professions | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 9 | 10% |
| Unknown | 20 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2012.
All research outputs
#13,366,719
of 22,675,759 outputs
Outputs from Advances in Therapy
#955
of 2,330 outputs
Outputs of similar age
#93,511
of 169,376 outputs
Outputs of similar age from Advances in Therapy
#11
of 22 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,330 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,376 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.